Search clinical trials for: (A) T-V14

Total 15229 results

JIANG LONGWEI
Nanjing University

Recruiting

A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors (Neoantigen-T)

Tumor, Solid

China
Antonio Pérez Martínez

Recruiting

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma (CAR4SAR)

Advanced Sarcoma

Spain
Shanghai Cell Therapy Group Co.,Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Simnova Biotechnology Co.,Ltd.
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recurrent Glioblastoma Multiforme

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of RD14-01 in Patients With Advanced Solid Tumors

Solid Tumor

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
iCell Gene Therapeutics
iCAR Bio Therapeutics Ltd. China

Recruiting

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

China
Crystal Mackall, MD

Recruiting

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

Brain and Nervous System

United States
Suzhou Immunofoco Biotechnology Co., Ltd
Changhai Hospital

Recruiting

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Gastric Cancer | Pancreatic Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Ovarian Carcinoma

China
Shanghai Mengchao Cancer Hospital
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Solid Tumor

China
Shenzhen University General Hospital

Recruiting

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (CAR-T)

Refractory Leukemia | Relapse Leukemia

China
Lion TCR Pte. Ltd.

Recruiting

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV) (SAFE-T-HBV)

Hepatocellular Carcinoma

Singapore
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
KAEDI

Not yet recruiting

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Glioma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor

China
Precigen, Inc

Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Stage III Fallopian Tube... and other conditions

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
UNC Lineberger Comprehensive Cancer Center

Recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin

United States
Sara V. Latorre
Instituto de Salud Carlos III

Completed

Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy (CART19-BE-01)

Lymphoma | Leukemia

Spain
Beaver-Visitec International, Inc.

Completed

Clinical Investigation of a Monofocal Toric Intra Ocular Lens (IOL) in Cataractous Eyes (PHY2107)

Cataract | Astigmatism | Lens Opacities

Japan
Autolus Limited

Enrolling by invitation

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

Multiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and Pediatric

United Kingdom
Children's Hospital Medical Center, Cincinnati
Hoxworth Blood Center

Completed

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

Allogeneic Stem Cell Transplant | Viral Infection

United States
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
University of Michigan
Blue Cross Blue Shield of Michigan Foundation

Completed

Pediatric Early Autism Recognition System: PEARS (PEARS)

Autism Spectrum Disorder

United States
Hospices Civils de Lyon

Withdrawn

Endogenous Retroviruses in Acute Myeloid Leukemia (ERVAL)

Leukemia, Myeloid
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...

Terminated

Study of LUCAR-20S in Patients With R/R NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
National Institute of Mental Health (NIMH)

Completed

Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)

Depression

United States
Eureka Therapeutics Inc.
Peking University

Completed

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
University of Pennsylvania

Terminated

Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant

Multiple Myeloma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease

United States
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Rabin Medical Center

Unknown

177Lu-PSMA-I&T Prior to Radical Prostatectomy for Locally Advanced Disease (NALuPROST)

Prostate Cancer

Israel
Nanjing First Hospital, Nanjing Medical University

Unknown

177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Peking University

Unknown

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Lymphoma

China
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
Celyad Oncology SA
National Heart, Lung, and Blood Institute (NHLBI); Dana-Farber Cancer Institute

Completed

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

Acute Myeloid Leukemia | Multiple Myeloma | Myelodysplastic Syndrome

United States
Milton S. Hershey Medical Center

Completed

Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

Cytomegalovirus Infections

United States
CHU de Reims

Unknown

The Role of Telemedical Monitoring in Diabetic Foot Ulcer Care (A15-06)

Diabetic Foot - Telemedical Monitoring

France
University of Cincinnati
National Institute on Drug Abuse (NIDA); Maryhaven

Unknown

Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction

Heroin Dependence | Opiate Dependence | Substance Dependence

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Johnson & Johnson Vision Care, Inc.

Completed

Mucin Balls and Corneal Inflammation Events

Corneal Infiltrative Events | Corneal Inflammation

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
Jessie L. Alexander

Active, not recruiting

Viral Specific T-Lymphocytes to Treat Adenovirus or CMV

Cytomegalovirus Infections | Adenovirus

United States
Columbia University
Roche Pharma AG

Completed

5th Generation cTnT in ED ACS

Acute Coronary Syndrome

United States
Shanghai GeneChem Co., Ltd.

Unknown

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Leukemia, B-Cell

China
M.D. Anderson Cancer Center

Active, not recruiting

Viral Specific T Cell Therapy for COVID-19 Related Pneumonia

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Coopervision, Inc.

Completed

Evaluation of Comfilcon A and Senofilcon A Lenses

Myopia

United States
Takeda

Completed

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)

Relapsing-Remitting Multiple Sclerosis

United States, Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Greece, Latvia, Macedonia, The Former Yugoslav Republic of, Mexico, Moldova, Republic of, Montenegro, Poland, Romania, Russian... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Relapse-Remitting Multiple Sclerosis

United States
University of Kansas Medical Center
In8bio Inc.

Recruiting

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States

Search clinical trials for: (A) T-V14

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations